Abstract：
Treating non-small-cell lung cancer (NSCLC) has gained increased importance in recent years due to the high mortality rate and dismal five-year survival rate. Immune checkpoint inhibitors (ICI) are a promising approach with exceptional outcomes in NSCLC thanks to the antigenic nature of cells. Conversely, immune system over-stimulation with ICI is a double-edged sword that can lead to various negative effects ranging from mild to life-threatening. This review explores current breakthroughs in nanoparticle-based ICI and their limitations. The PubMed, Scopus and Web of Science were examined for relevant publications. Thirty-eight trials (N = 16,781) were included in the analyses. The mixed effects analyses on quantifying the treatment effect contributed significantly to the subgroups within studies for ICI treatment effect. Models confirmed ICI\'s higher impact on treatment effectivity and the decrease in respondents\' mortality compared to conventional treatment regiments. ICI might be used as first-line therapy due to their proven effectiveness and safety profile.
摘要：
近年来，由于高死亡率和令人沮丧的五年生存率，治疗非小细胞肺癌（NSCLC）的重要性日益增加。免疫检查点抑制剂（ICI）是一种有前途的方法，由于细胞的抗原性，在NSCLC中具有出色的结果。相反，ICI对免疫系统的过度刺激是一把双刃剑，可导致从轻度到危及生命的各种负面影响。这篇综述探讨了基于纳米粒子的ICI的当前突破及其局限性。PubMed,检查了Scopus和WebofScience的相关出版物。分析中包括38项试验(N=16,781)。量化治疗效果的混合效果分析对ICI治疗效果研究中的亚组做出了显着贡献。模型证实，与常规治疗方案相比，ICI对治疗效果的影响更大，且降低了受访者的死亡率。由于ICI已被证明的有效性和安全性，ICI可能被用作一线治疗。
